ArticleFrontiers in pharmacology2022
Combination of
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs.Journal of medicine and life · 2023Pooled it
- Cardioprotective effects of notoginsenoside R1 on myocardial remodeling and cardiac function in restraint stress-induced MI in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ginseng Biomacromolecules: Integrating Nutrition and Health, a New Direction in Phytomedicine.International journal of molecular sciences · 2026Review
- Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity.Molecules (Basel, Switzerland) · 2025Review
- Evaluating the renoprotective effects of omega-3-6-9 against cisplatin-induced nephrotoxicity in mice.Journal of medicine and life · 2023Article
- Neuroprotective effects of daidzein against ifosfamide-induced neurotoxicity in male rats: role of selected inflammatory and apoptotic markers.Journal of medicine and life · 2023Article
- Evaluating the effect of ursodeoxycholic acid (UDCA) in comparison with dexamethasone and diclofenac in a rat model of rheumatoid arthritis.Journal of medicine and life · 2023Article
- Protective effect of citronellol in rhabdomyolysis-induced acute kidney injury in mice.Journal of medicine and life · 2023Article
- Mucoprotective effect of ellagic acid in 5 fluorouracil-induced intestinal mucositis model.Journal of medicine and life · 2023Article
- The role of ginseng derivatives against chemotherapy-induced cardiotoxicity: A systematic review of non-clinical studies.Frontiers in cardiovascular medicine · 2023Review
- Hepatoprotective potential ofToxicology reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is an anticancer agent for treating solid and soft tissue malignancies. However, the clinical use of DOX is restricted by cumulative, dose-dependent cardiotoxicity. Therefore, the present study aimed to assess the cardioprotective effects of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.